Groth Allyson D, Contreras Marcos T, Kado-Fong Helen K, Nguyen Kyvan Q, Thomasy Sara M, Maggs David J
Veterinary Medical Teaching Hospital, University of California, Davis, Davis, CA, 95616, USA.
Vet Ophthalmol. 2014 Jul;17(4):268-74. doi: 10.1111/vop.12094. Epub 2013 Sep 23.
To assess in vitro the antiviral efficacy against feline herpesvirus (FHV-1) and cytotoxicity for cultured feline cells of famciclovir and its metabolites, BRL 42359 and penciclovir. To investigate the effect of timing of penciclovir application on in vitro antiviral activity.
Plaque reduction assays were used to estimate antiviral efficacy of all compounds and the effect of penciclovir exposure before or after exposure to a FHV-1 field isolate. Cytotoxicity was evaluated by assessing cell morphology and viable cell number for 72 h following exposure to each compound.
The penciclovir concentration that inhibited FHV-1-induced plaque formation by 50% (IC50 ) was 0.86 μg/mL (3.4 μm). Famciclovir and BRL 42359 had no antiviral effect against FHV-1 at any concentration assessed. Antiviral activity was significantly enhanced when cells were exposed to 4 μm penciclovir (approximate IC50 ) for 1 h but not for 24 h before viral adsorption. Delaying exposure of cells to penciclovir for 1, 2, or 4 h after viral adsorption significantly enhanced antiviral activity. Relative to untreated control wells, >88% of cells remained viable when exposed to famciclovir (100 μm), BRL 42359 (1.06 mm), or penciclovir (40 μm) for 72 h. No morphologic evidence of cytotoxicity was noted.
Penciclovir demonstrates potent antiviral activity against FHV-1 and may be effective at lower tissue, tear, and plasma concentrations than previously targeted. The duration of in vitro antiviral effect of penciclovir suggests that frequent famciclovir administration may be necessary in vivo. Famciclovir and BRL 42359 showed no signs of in vitro cytotoxicity.
在体外评估泛昔洛韦及其代谢产物BRL 42359和喷昔洛韦对猫疱疹病毒(FHV - 1)的抗病毒效力以及对培养猫细胞的细胞毒性。研究喷昔洛韦应用时间对体外抗病毒活性的影响。
采用蚀斑减少试验评估所有化合物的抗病毒效力以及喷昔洛韦在暴露于FHV - 1野外分离株之前或之后暴露的影响。通过评估暴露于每种化合物后72小时的细胞形态和活细胞数量来评价细胞毒性。
抑制FHV - 1诱导蚀斑形成50%(IC50)的喷昔洛韦浓度为0.86μg/mL(3.4μm)。在评估的任何浓度下,泛昔洛韦和BRL 42359对FHV - 1均无抗病毒作用。当细胞在病毒吸附前暴露于4μm喷昔洛韦(约IC50)1小时而非24小时时,抗病毒活性显著增强。在病毒吸附后将细胞暴露于喷昔洛韦1、2或4小时可显著增强抗病毒活性。相对于未处理的对照孔,当暴露于泛昔洛韦(100μm)、BRL 42359(1.06mm)或喷昔洛韦(40μm)72小时时,>88%的细胞仍保持存活。未观察到细胞毒性的形态学证据。
喷昔洛韦对FHV - 1显示出强大的抗病毒活性,并且在低于先前目标的组织、泪液和血浆浓度下可能有效。喷昔洛韦体外抗病毒作用的持续时间表明,在体内可能需要频繁给予泛昔洛韦。泛昔洛韦和BRL 42359未显示出体外细胞毒性迹象。